Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,609 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. Rudin CM, et al. Among authors: ozawa y. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17. J Clin Oncol. 2024. PMID: 37976444 Free PMC article. Clinical Trial.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Heymach JV, et al. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. N Engl J Med. 2023. PMID: 37870974 Clinical Trial.
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S, Inui N, Ozawa Y, Nakamura Y, Toyoshima M, Yasuda K, Yamada T, Shirai T, Suganuma H, Yokomura K, Suda T, Chida K. Matsuura S, et al. Among authors: ozawa y. Jpn J Clin Oncol. 2011 Aug;41(8):959-63. doi: 10.1093/jjco/hyr079. Epub 2011 Jun 28. Jpn J Clin Oncol. 2011. PMID: 21715361 Clinical Trial.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: ozawa y. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Hayashi H, et al. Among authors: ozawa y. Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194. Clin Cancer Res. 2022. PMID: 34921023 Free PMC article. Clinical Trial.
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Among authors: ozawa y. Clin Lung Cancer. 2021 Nov;22(6):e833-e841. doi: 10.1016/j.cllc.2021.04.007. Epub 2021 Apr 27. Clin Lung Cancer. 2021. PMID: 34049821 Free article.
1,609 results